NovaBay Pharmaceuticals, Inc.
NBY · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1 | $0 | $0 | $2 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $1 |
| Gross Profit | $0 | $0 | $0 | $2 |
| % Margin | 8.1% | – | – | 65% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $1 | $2 | $3 | $2 |
| SG&A Expenses | $1 | $2 | $3 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $1 |
| Other Operating Expenses | $0 | $0 | $1 | $0 |
| Operating Expenses | $1 | $2 | $3 | $3 |
| Operating Income | -$1 | -$2 | -$3 | -$1 |
| % Margin | -241.1% | – | – | -55.8% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$1 | -$2 | -$3 | -$1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1 | -$2 | $8 | -$1 |
| % Margin | -248.2% | – | – | -52.5% |
| EPS | -0.22 | -0.33 | 1.44 | -0.27 |
| % Growth | 33.3% | -122.9% | 633.3% | – |
| EPS Diluted | -0.22 | -0.33 | 1.42 | -0.27 |
| Weighted Avg Shares Out | 6 | 6 | 5 | 5 |
| Weighted Avg Shares Out Dil | 6 | 6 | 5 | 5 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | -$2 | -$3 | -$1 |
| % Margin | -255.5% | – | – | -51.8% |